Keyphrases
Familial Mediterranean Fever
100%
Treatment-related
100%
Anakinra
100%
IL-1 Blockers
37%
Colchicine
25%
AL Amyloidosis
25%
Pediatric Patients
12%
Overproduction
12%
Monogenic
12%
Own Experience
12%
Clinical Setting
12%
Safety Concerns
12%
PubMed
12%
Interleukin-1β
12%
Clinical Management
12%
Leg Pain
12%
Published Data
12%
On Demand
12%
Clinical Aspects
12%
Arthritis
12%
Short Half-life
12%
Recombinant Form
12%
Clinical Genetics
12%
Interleukin-1 Receptor Antagonist (IL-1Ra)
12%
Unresponsiveness
12%
Renal Transplantation
12%
Lactation
12%
Chronic Inflammation
12%
Genetic Aspects
12%
Autoinflammatory
12%
Colchicine Resistance
12%
Protracted Febrile Myalgia
12%
Short-term Use
12%
Management Aspects
12%
Recurrent Inflammation
12%
Canakinumab
12%
Fever Treatment
12%
Pyrin Inflammasome
12%
Pharmacology, Toxicology and Pharmaceutical Science
Familial Mediterranean Fever
100%
Anakinra
100%
Diseases
100%
Interleukin 1
50%
Colchicine
37%
Amyloid Protein
25%
Amyloidosis
12%
Leg Pain
12%
Arthritis
12%
Inflammasome
12%
Interleukin 1 Receptor Blocking Agent
12%
Myalgia
12%
Chronic Inflammation
12%
Pyrin
12%
Kidney Amyloidosis
12%
Canakinumab
12%
Immunology and Microbiology
Familial Mediterranean Fever
100%
Anakinra
100%
Interleukin 1
50%
Colchicine
37%
Amyloidosis
25%
Leg
12%
Arthritis
12%
Medline
12%
Kidney Transplantation
12%
Interleukin 1 Receptor Antagonist
12%
Canakinumab
12%
Inflammasome
12%